Last update May 13, 2019

Corifollitropin Alfa

Low Risk

Possibly safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.

Follicle stimulating hormone (FSH) or follitropin is a hormone of the gonadotropin type, which is found normally in the body. It is synthesized and secreted by gonadotroph cells from the anterior part of the pituitary gland.
FSH regulates pubertal maturation. In women, it matures the oocytes of the ovary and stimulates the production of estradiol (estrogen hormone). In men it regulates the production of sperm.

CORIFOLITROPIN is an FSH obtained by recombinant engineering, like follitropin alpha, beta and delta. Its efficacy and indications are the same, but as it is long-acting, it is more comfortable and reduces the number of injections (Benchabane 2017, Cruz 2017, Griesinger 2016).
It is used in infertility treatments to induce ovulation in anovulatory patients and for the development of multiple follicles (ovarian hyperstimulation) in ovulatory patients in assisted reproduction programmes.
Subcutaneous administration in a single dose. Subsequently (after 5-6 days) the human chorionic gonadotropin (hCG) is administered to trigger ovulation.

Since the last update we have not found any published data on its excretion in breast milk.

Its high molecular weight makes its excretion in breastmilk very unlikely.

Due to its proteinaceous nature it is inactivated in the gastrointestinal tract, not being absorbed, (oral bioavailability is practically zero), which impedes transfer to infant plasma from breastmilk, except in premature babies and the immediate neonatal period, when there may be more intestinal permeability.

There is no proof that its estrogenic effects decrease milk production.
-------------------------------------------------- --------


In assisted reproduction treatments (ART) for infertility, two issues must be taken into account:

1. The possible effects of ART on the infant or breastfeeding.
The medication used, in general, does not interfere with breastfeeding and does not affect the infant, who in these cases is usually older than 6 months and even 1 or 2 years old.

2. The possible interference of breastfeeding with ART.
Breastfeeding, especially frequent, could hinder ovulation. This is the main reason why assisted reproduction services recommend suspending breastfeeding before starting treatment which is usually emotionally costly and, often, also from a financial perspective.

To date, there is no published data that proves that breastfeeding is incompatible with assisted reproduction techniques (ART).

See below the information of these related products:


We do not have alternatives for Corifollitropin Alfa.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Corifollitropin Alfa is also known as

Corifollitropin Alfa in other languages or writings:


Corifollitropin Alfa belongs to this group or family:


Main tradenames from several countries containing Corifollitropin Alfa in its composition:


Variable Value Unit
Oral Bioavail. 0 %
Molecular weight 25.398 daltons
VD 0.15 (0.11 - 0.22) l/Kg
Tmax 44 (35 - 57) hours
70 (59 - 82) hours


  1. MSD. Corifollitropin (Elonva) Drug Summary. 2017 Full text (in our servers)
  2. Benchabane M, Santulli P, Maignien C, Bourdon M, De Ziegler D, Chapron C, Gayet V. [Corifollitropin alfa compared to daily FSH in controlled ovarian stimulation for oocyte donors]. Gynecol Obstet Fertil Senol. 2017 Feb;45(2):83-88. Abstract
  3. Cruz M, Alamá P, Muñoz M, Collado D, Blanes C, Solbes E, Requena A. Economic impact of ovarian stimulation with corifollitropin alfa versus conventional daily gonadotropins in oocyte donors: a randomized study. Reprod Biomed Online. 2017 Jun;34(6):605-610. Abstract
  4. Griesinger G, Boostanfar R, Gordon K, Gates D, McCrary Sisk C, Stegmann BJ. Corifollitropin alfa versus recombinant follicle-stimulating hormone: an individual patient data meta-analysis. Reprod Biomed Online. 2016 Jul;33(1):56-60. Abstract
  5. EMA - MSD. Corifolitropina (Elonva). Ficha técnica. 2014 Full text (in our servers)

Total visits


Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at

e-lactancia is a resource recommended by El Parto Es Nuestro of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM